FDA Approves PET Test for Alzheimer: WMIS Welcomes the Development

Share Article

FDA had approved the long-awaited diagnostic/detection test for Alzheimer. The test was developed by Eli Lilly & Co.

FDA had approved the long-awaited diagnostic/detection test for Alzheimer. The test was developed by Eli Lilly & Co. Lilly acquired Avid, the pioneer company which led the research for the diagnostic test.

This test is performed using the PET (Positron Emission Tomography) modality. The imaging agent known as Amyvid lights up deposits of beta amyloid in brain scans. Beta Amyloid is the protein that is present in Alzheimer patients.

The test can be used to determine two conditions. First, the absence of beta amyloid can be used to rule out Alzheimer. Second, the presence of beta amyloid can indicate the possibility of Alzheimer. The presence of beta amyloid doesn't always mean that the patient has Alzheimer. Hence the test can be used along with other tests to provide a data point which can lead to the diagnosis of Alzheimer.

Over 5 million Americans suffer from Alzheimer and the statistics indicate that the disease is expected to rise fast as the average age of population increases. President Obama has set a national target of preventing and treating Alzheimer by 2025.

World Molecular Imaging Society (WMIS) welcomes the new developments in the PET arena. WMIS is playing a critical role in helping patients, physicians, regulators, and researchers understand and develop a coordinated strategy for fight against Alzheimer. WMIS organized a scientific conference in Chicago in March 2012 focused on Alzheimer and beta amyloid. The society is now working with the world's most innovative companies to accelerate the adoption of novel solutions for Alzheimer patients.    

WMIS (World Molecular Imaging Society) is the world's most innovative and leading society in molecular imaging and molecular medicine. With the rise of the molecular imaging industry and the associated research, WMIS is the only organization that is connecting all the dots in the industry and is working to bring all stakeholders together by Smashing the Silos and Leading Innovation Convergence in molecular medicine; both for practitioners and researchers, who are defining the future of molecular imaging, WMIS enhances the potential and applications of innovation.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Al Naqvi
WMIS
703-421-2229
Email >